OTC:KBLB
Kraig Biocraft Laboratories, Inc.
A biotech developer specializing in patented cell therapies and agricultural innovations with substantial cash reserves but currently operating at a net loss.
Key Metrics
Investment Thesis
Bull Case
Investors might consider KBLB due to its extensive patent portfolio representing significant long-term value that could unlock substantial returns upon successful commercialization. The substantial shareholders equity of $32.6M provides a cushion against operational losses and funds future development without immediate dilution concerns. Early-stage biotech stocks often offer asymmetric upside potential if key products achieve regulatory approval and market traction.
Bear Case
The stock presents severe downside risk given the consistent net losses exceeding $3M annually and current liabilities significantly outweighing liquid assets. With zero revenue in recent periods, the company lacks sustainable business model validation necessary for long-term viability in a capital-intensive biotech sector. Historical financial trends show deteriorating profitability with no clear path to positive cash flow generation within foreseeable horizons.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (KBLB) is a biotechnology firm focused on developing proprietary cell-based therapies and agricultural solutions, primarily serving markets in regenerative medicine and sustainable farming. The company leverages its patented technology to create functionalized cells for tissue repair and bio-fertilizer applications. Despite minimal recent revenue generation, the entity maintains significant equity reserves and active R&D programs.
Analysis
Management Discussion
Financial performance remains challenging with net profits declining from -$3.8M in 2022 to -$3.4M in 2024, reflecting continued heavy investment in R&D and operations without corresponding revenue growth. The cash burn rate is exacerbated by negative financing cash flows of $35k and minimal operating income, indicating reliance on external capital or equity dilution for survival. Despite these pressures, the company maintains a positive working capital position through non-cash adjustments totaling $0.8M.
Industry Overview
The global regenerative medicine and agricultural biotechnology sectors are experiencing rapid growth driven by aging demographics and increasing demand for sustainable farming solutions. However, these industries remain highly competitive with high barriers to entry requiring substantial R&D investment and lengthy regulatory approval processes. Market consolidation is expected as smaller players struggle to secure adequate funding without proven commercial products.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $2.1M | $2.6M | $3.1M |
| Operating Income | $-2.1M | $-2.6M | $-3.1M |
| R&D | $176.4K | $237.9K | $164.4K |
| G&A | $825.5K | $1.5M | $1.7M |
| Depreciation | $28.1K | $27.6K | $26.2K |
| Other OpEx | $1.1M | $922.6K | $1.2M |
| Non-Operating Income | $-1.7M | $-415.0K | $-324.4K |
| Pre-Tax Income | $-3.8M | $-3.0M | $-3.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-3.8M | $-3.0M | $-3.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-3.8M | $-3.0M | $-3.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-3.8M | $-3.0M | $-3.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $4.0M | $2.6M | $740.3K |
| Cash & Equivalents | — | $2.6M | $673.3K |
| Inventory | $6.6K | $6.9K | $6.9K |
| Other Current Assets | $4.0M | $14.9K | $60.1K |
| Long-Term Assets | $587.5K | $659.2K | $765.0K |
| PP&E (Net) | $87.9K | $66.6K | $44.7K |
| Operating Leases | $58.8K | $95.8K | $86.1K |
| Other LT Assets | $440.8K | $496.8K | $634.2K |
| Total Assets | $4.6M | $3.2M | $1.5M |
| Current Liabilities | $8.1M | $8.9M | $9.6M |
| Current Leases | $39.2K | $41.8K | $46.9K |
| Other Current Liab | $7.9M | $8.8M | $9.6M |
| Long-Term Liabilities | $20.7K | $54.4K | $40.5K |
| LT Operating Leases | $20.7K | $54.4K | $40.5K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $8.1M | $8.9M | $9.7M |
| Shareholders' Equity | $-3.5M | $-5.7M | $-8.1M |
| Paid-In Capital | $10.8M | $11.4M | $12.3M |
| Retained Earnings | $-46.7M | $-49.7M | $-53.1M |
| Total L&E | $4.6M | $3.2M | $1.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-3.8M | $-3.0M | $-3.4M |
| Non-Cash Adjustments | $1.5M | $961.0K | $780.2K |
| Working Capital Changes | $476.7K | $824.3K | $779.6K |
| Cash from Operations | $-1.9M | $-1.2M | $-1.8M |
| Capital Expenditures | $5.0K | $6.4K | $4.2K |
| Cash from Investing | $-5.0K | $-6.4K | $-4.2K |
| Cash from Financing | $3.4M | $-60.0K | $-35.2K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $1.5M | $-1.3M | $-1.9M |
| Beginning Cash | $2.4M | $3.9M | $2.6M |
| Ending Cash | $3.9M | $2.6M | $673.3K |
Frequently Asked Questions
How does Kraig Biocraft Laboratories, Inc. make money?
The company's operations are segmented into proprietary cell therapy development for regenerative medicine applications and specialized agricultural solutions including bio-fertilizers derived from functionalized cells. A third segment involves strategic licensing of intellectual property to external partners to monetize technology without direct product sales. Final activities include administrative overhead management and potential government contract support related to their biotechnology research.
What are the main risks for KBLB?
The company faces significant liquidity risks due to negative operating cash flows of $1.8M and substantial current liabilities exceeding current assets by nearly $9M. Ongoing research and development expenses totaling $0.2M annually may not be sufficient to generate revenue without successful commercialization or major funding rounds. Regulatory approval uncertainties for cell-based therapies pose a threat to future product launches and market entry timelines.
What is KBLB's competitive advantage?
The firm holds a robust portfolio of 32 issued patents covering cell therapy processes and agricultural applications that protect its core technology from competitors. Its unique functionalization platform allows for precise control over cell behavior, offering a distinct advantage in developing targeted treatments for tissue regeneration. The company benefits from a diversified intellectual property strategy that includes both therapeutic and agricultural IP portfolios.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.